-
In order to optimize the asset structure, the pharmaceutical company intends to sell some API production plant assets
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Recently, the API industry has been dynamic, including Xinhua Pharmaceutical, Xintiandi Pharmaceutical and other pharmaceutical companies have expressed plans to build production bases in order to break through development.
-
Application of fire emergency lighting and evacuation indication system in a pharmaceutical plant project
Time of Update: 2022-10-02
In order to ensure that the equipment is in a normal state when the fire occurs, can work normally, the implementation of rapid and reasonable emergency evacuation system, centralized control type emergency lighting and evacuation indication system came into being, can accurately realize the real-time monitoring and control of each emergency lamp, daily 24-hour management and maintenance, to ensure that the system operates normally, in the event of a fire accurately and quickly guide personnel to the safe area.
-
Keji Pharmaceutical's US CGMP production plant completed the first clinical batch production of CAR-T products
Time of Update: 2022-09-06
Exterior view of Keji Pharmaceutical's CGMP production plant The RTP GMP production facility, with a total construction area of approximately 3,300 square meters, will provide Keji Pharmaceuticals with additional capacity to produce autologous CAR-T cell products for 700 patients per year to support clinical research and early commercial use in North America and Europe change .
-
[Shinei Group] Whole Plant Planning Case-Pharmaceutical Industry
Time of Update: 2022-08-21
The whole plan integrates water, electricity, gas and central raw material processing systems In 2019, our company reached a cooperation with the company and planned a whole plant plan of 7 injection blowers for it.
-
Entering the fast lane of development, Keji Pharmaceutical's first overseas cGMP production plant started operation in the United States!
Time of Update: 2022-05-28
Officials from the local government and economic development departments of North Carolina and Durham, the United States, the service providers related to the construction of the RTP production plant, and Keji Pharmaceutical USA Important partners of the company attended the ceremony together .
-
Keji Pharmaceutical's first overseas cGMP production plant starts operation in the United States, accelerating its global layout
Time of Update: 2022-05-02
HK), a company primarily focused on the treatment of hematological malignancies and solid tumors An innovative CAR-T cell therapy company, announced today that the cGMP production plant (hereinafter referred to as the "RTP production plant") built by the company's American company CARsgen Therapeutics Corporation in the Research Triangle Park (RTP) area of North Carolina, USA has passed the official inspection of the local government .
-
Shaanxi Kangcheng Pharmaceutical-Plant extraction and processing investment, welcome to cooperate!
Time of Update: 2021-11-15
The company is located in Jinghe Ecological Industrial Park, Shangzhou District, Shangluo City, Shaanxi Province, covering an area of 118 acres, with a total construction area of 70,000 square meters; of which, the area of production workshops and storage buildings is 44,000 square meters; the area of office and service buildings is 26,000 square meters; The total construction investment is 320 million yuan .
-
Wuxi Wuxi AppTec obtains production license for German pharmaceutical production plant
Time of Update: 2021-07-30
Chris Chen, Chief Executive Officer of Wuxi WuXi Pharmaceutical, said: "We are very pleased that the DP7 plant in Leverkusen has successfully passed the EU regulatory agency's GMP inspection for the commercial production of biologics.
-
N-Glycosylation of Plant Recombinant Pharmaceuticals
Time of Update: 2021-03-12
N -glycosylation is a maturation event necessary for the correct function, efficiency, and stability of a high number of biopharmaceuticals.
This chapter presented here proposes various methods to determine whether, how, and where a plant pharmaceutical isN -glycosylated.
-
Pharmaceutical Bio's 150 million euro acquisition of Bayer Biopharmaceity's original liquid plant
Time of Update: 2021-03-09
MFG19 will join forces with the Biologics Plant (DP7) in Leverkusen, Germany, to help Pharmaceuticals provide commercial production services.
MFG19 and DP7 are expected to go into production in 2021, providing strong support for the European production supply chain for pharmaceutical products.
-
Xianle Pharmaceutical pioneered the revolutionary plant glue softgels
Time of Update: 2021-02-03
In recent years, with the popularity of pure natural and vegetarian concepts, plant glue softgels have attracted widespread attention in developed countries such as Europe and the United States, and b
-
This pharmaceutical company intends to start the first phase of the construction project
Time of Update: 2020-11-16
In order to support the company's preparation CDMO business planning and development, with preparation GMP production and release capacity, Boten Pharmaceuticals intends to invest about 278 million yuan in Chongqing Two Rivers New Area to start the first phase of the preparation plant construction project, in order to build the preparation CDMO service capacity, to undertake from IND to NDA and even commercial phase of the preparation outsourcing project, thereby enhancing the company's integrated delivery capacity.
-
A Case Study for Plant-Made Pharmaceuticals Comparing Different Plant Expression and Production Systems
Time of Update: 2020-11-13
Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated in a range of plant crops.
Each of the protein manufacturing platforms in plants has specific benefits and drawbacks.
-
Rapid System for Evaluating Bioproduction Capacity of Complex Pharmaceutical Proteins in Plants
Time of Update: 2020-11-09
We have optimized a simple transient expression system inNicotiana benthamiana enabling rapid assessment of transgene potential for plant-based bioproduction.
This system provides a rapid source of transgene product for assessing posttranslational modifications, purification strategies, and bioactivity as well as an effective system for optimizing construct elements.
-
Biosafety, Risk Assessment and Regulation of Plant-Made Pharmaceuticals
Time of Update: 2020-11-04
Transgenic Res ., 2007), with specific guidelines currently being drawn up for the regulation of PMPs. In this chapter, we provide an overview of the biosafety ( see Note3 ), risk assessment ( see Note4 ) and regulation of this emerging technology.